Efficacy And Safety Analysis Of Bortezomib Based Chemotherapy In The Treatment Of Multiple Myeloma

Objective: Explore the efficacy and safety of bortezomib based chemotherapy regimens in the treatment of multiple myeloma.Methods:In this retrospective study From 11/2009 to 11/2016,we collected clinical datas of 51 MM patients treated with bortezomib based chemotherapy regimens for more than four courses from the first affiliated hospital of Guangxi medical university.The basic conditions of the survival patients were followed and used the kaplan-meier method for survival analysis,and the correlation factors affecting the prognosis were determined by using the log-rank test.Results: 1.The efficacy of bortezomib based chemotherapy regimens in the treatment of multiple myeloma: 51 MM patients were evaluated overall effect after 4 cycles of chemotherapy.the CR rate and total response rate of the untreated patients were 23.5% and 86.3%.The three-year survival rate was68.7% and 31.1% for the five-year survival rate.The median OS and median PFS in the 51 MM patients were 61 months and 32 months respectively.2.The correlation factors affecting the prognosis of bortezomib based chemotherapy regimens: PFS was significantly higher than the no meet VGPRgroup in the CR and VGPR group(40 VS 16,P=0.001).As for OS,Beta 2microglobulin < 5.5 mg/L is significantly higher than patients with beta 2microglobulin > 5.5 mg/L group(76 VS 37,P=0.004);The patients with non-severe anemia were significantly higher than those with severe anemia(61VS 28,P=0.017);Group A in the DS was higher than group B(61 VS 17,P=0.001).3.The adverse reactions of bortezomib based chemotherapy regimens :51MM patients received 70.6% adverse reactions after bortezomib chemotherapy.The main adverse reactions were leukopenia,fatigue,peripheral neuritis and infection,its incidence was 23.5%,19.6%,17.6%,15.7%.Conclusion: 1.The treatment of the MM with borotizolmi chemotherapy was effective.2.Patients with no VGPR and beta 2 microglobulin increasing,severe anemia and Kidney serious damage did not have a good prognosis.3.Bortezomib based chemotherapy regimens in the treatment of multiple myeloma were safe.